Alumis Q2 Loss Widens on $41.8M Impairment; Cash Runway Extends to 2027
ALMS has more than doubled off its 52-week low of $3.76.
Summary
Alumis posted a wider Q2 loss on a $41.8M impairment of its lonigutamab asset, but its $502.3M cash position provides runway into 2027. The company reaffirmed plans to submit an NDA for envu in Q4 2026.
Key Events · Earnings and Guidance · ALMS
-
Q2 Net Loss of $142.2M
Net loss widened from a $59.3M profit a year ago, driven by a $41.8M intangible asset impairment charge related to the lonigutamab program.
-
Lonigutamab Impairment
The company recorded a $41.8M impairment after deciding to pursue strategic alternatives for lonigutamab, reducing the asset's carrying value to $9.1M.
-
Cash Runway
Cash, cash equivalents and marketable securities totaled $502.3M as of June 30, 2026, which management says is sufficient for at least 12 months.
-
Envu NDA on Track
The company plans to submit an NDA for envu in moderate-to-severe plaque psoriasis in Q4 2026, following positive ONWARD3 LTE data reported in August 2026.
Analysis · ALMS · Life Sciences
Alumis reported a Q2 net loss of $142.2 million, driven by a $41.8 million impairment charge after deciding to pursue strategic alternatives for the lonigutamab program. The company holds $502.3 million in cash and marketable securities, which it says funds operations for at least 12 months. Positive ONWARD3 data and a planned Q4 NDA submission for envu in psoriasis keep the lead program on track.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALMS was trading at $24.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $3.76 to $31.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.